# Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo

> **NCT04971200** · EARLY_PHASE1 · COMPLETED · sponsor: **Premier Specialists, Australia** · enrollment: 12 (actual)

## Conditions studied

- Skin and Connective Tissue Diseases
- Skin Diseases
- Pigmentation Disorder
- Hypopigmentation
- Biologic
- Vitiligo

## Interventions

- **DRUG:** Tildrakizumab

## Key facts

- **NCT ID:** NCT04971200
- **Lead sponsor:** Premier Specialists, Australia
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-16
- **Primary completion:** 2024-11-10
- **Final completion:** 2024-11-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04971200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04971200, "Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04971200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*